87 results on '"Tribius, Silke"'
Search Results
52. Long-term radiation sequelae after breast-conserving therapy in women with early-stage breast cancer: an observational study using the LENT-SOMA scoring system
53. Cosmesis from the patient's and the doctor's view
54. HPV and Oropharyngeal Cancer in the Eighth Edition of the TNM Classification: Pitfalls in Practice
55. Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).
56. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.
57. ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture
58. HPV bei Oropharynxkarzinomen in der 8. Ausgabe der TNM-Klassifikation
59. Influence of HPV-status on survival of patients with tonsillar carcinomas (TSCC) treated by CO 2 -laser surgery plus risk adapted therapy - A 10 year retrospective single centre study
60. Standard or split TPF induction chemotherapy followed by bioradiation: ICRAT randomized phase II study.
61. Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer
62. Toll-like-Rezeptor 3 und 7 vermittelte Biosynthese des Tumormikromilieus in HPV-assoziierten Kopf-Hals-Karzinomen
63. Bedeutung der klinischen Untersuchung, Patientenangabe, radiologischer Diagnostik (CT) und Panendoskopie in der Nachsorge von Kopf-Hals-Tumorpatienten
64. Das sinunasale undifferenzierte Karzinom (SNUC), eine seltene Differentialdiagnose der Tumore der Nase/Nasennebenhöhlen. 2 Fallberichte und Literaturübersicht
65. Outcome and fewer indications for adjuvant therapy for patients with oral squamous cell carcinomas under standardized tumor board conditions
66. Comparison of Standard to Split-Dose TPF Induction Chemotherapy followed by Bio-radiation for LASCC of the Head and Neck: Results of the ICRAT randomized Phase II Study.
67. Is immediate bony microsurgical reconstruction after head and neck tumor ablation associated with a higher rate of local recurrence?
68. Survival analysis of 287 oropharyngeal squamous cell carcinoma patients in a single institution: a retrospective comparison of two consecutive time intervals with surgical and conservative treatment approaches.
69. Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in Germany
70. Significance of panendoscopy and CT in the follow-up and management of squamous cell carcinoma of the head and neck: A retrospective clinical assessment.
71. OP234
72. Human Papilloma Virus Infection in Head and Neck Cancer
73. Human papillomavirus infection in head and neck cancer: The role of the secretory leukocyte protease inhibitor
74. Five years' results of the German ARO 04-01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer.
75. Molecular targeting agents in the context of primary chemoradiation strategies
76. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: Is there a worthwhile quality of life gain?
77. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: What we know and what we need to know
78. Geographical and anatomical influences on human papillomavirus prevalence diversity in head and neck squamous cell carcinoma in Germany.
79. Epoetin alfa improves survival after chemoradiation for Stage III esophageal cancer: Final results of a prospective observational study
80. Is there a life-long risk of brachial plexopathy after radiotherapy of supraclavicular lymph nodes in breast cancer patients?
81. OP234: 5-Years’ Results of the German Head and Neck Cooperative Trials Group ARO 04-01 of concurrent 72 Gy HART/cis-Platinum/5-FU vs. HART/Mitomycin/5-FU in LAD H&N cancer
82. HPV DNA, E6*I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer – How valid is p16INK4A as surrogate marker?
83. Spätnebenwirkungen und Kosmetik nach konventioneller versus hypofraktionierter Bestrahlung im Rahmen der brusterhaltenden Therapie des Mammakarzinoms
84. Evidence-based approach to determine meaningful change in scores of the EORTC QLQ-C30 in breast and head and neck cancer: on behalf of the EORTC Breast, Head and Neck and Quality of Life Groups
85. Influence of HPV-status on survival of patients with tonsillar carcinomas (TSCC) treated by CO2-laser surgery plus risk adapted therapy - A 10 year retrospective single centre study.
86. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer.
87. [HPV and oropharyngeal squamous cell cancer in the 8th edition of the TNM classification].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.